560 related articles for article (PubMed ID: 30602372)
1. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
Al-Khadairi G; Naik A; Thomas R; Al-Sulaiti B; Rizly S; Decock J
J Transl Med; 2019 Jan; 17(1):9. PubMed ID: 30602372
[TBL] [Abstract][Full Text] [Related]
2. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
[TBL] [Abstract][Full Text] [Related]
3. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Nam SJ; Lee JE
Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
[TBL] [Abstract][Full Text] [Related]
4. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition.
Wang H; Sang M; Geng C; Liu F; Gu L; Shan B
Neoplasma; 2016; 63(1):44-56. PubMed ID: 26639233
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway.
Wang L; Kang FB; Wang J; Yang C; He DW
Anticancer Drugs; 2019 Mar; 30(3):225-232. PubMed ID: 30334817
[TBL] [Abstract][Full Text] [Related]
6. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
[TBL] [Abstract][Full Text] [Related]
7. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of MGP by HOXC8 promotes the proliferation, migration, and EMT processes of triple-negative breast cancer.
Gong C; Zou J; Zhang M; Zhang J; Xu S; Zhu S; Yang M; Li D; Wang Y; Shi J; Li Y
Mol Carcinog; 2019 Oct; 58(10):1863-1875. PubMed ID: 31264274
[TBL] [Abstract][Full Text] [Related]
9. TLR5: A prognostic and monitoring indicator for triple-negative breast cancer.
Shi D; Zhao S; Jiang W; Zhang C; Liang T; Hou G
Cell Death Dis; 2019 Dec; 10(12):954. PubMed ID: 31852883
[TBL] [Abstract][Full Text] [Related]
10. Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial-mesenchymal transition in triple-negative breast cancer.
Lv ZD; Yang ZC; Liu XP; Jin LY; Dong Q; Qu HL; Li FN; Kong B; Sun J; Zhao JJ; Wang HB
J Cell Mol Med; 2016 Sep; 20(9):1640-50. PubMed ID: 27027510
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of NuSAP1 is predictive of an unfavourable prognosis and promotes proliferation and invasion of triple-negative breast cancer cells via the Wnt/β-catenin/EMT signalling axis.
Sun L; Shi C; Liu S; Zhang E; Yan L; Ji C; Zhao Y
Gene; 2020 Jul; 747():144657. PubMed ID: 32298762
[TBL] [Abstract][Full Text] [Related]
12. STAT3 Targets
Ma JH; Qi J; Lin SQ; Zhang CY; Liu FY; Xie WD; Li X
Mol Cancer Res; 2019 Nov; 17(11):2184-2195. PubMed ID: 31427441
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition.
Das K; Paul S; Singh A; Ghosh A; Roy A; Ansari SA; Prasad R; Mukherjee A; Sen P
J Biol Chem; 2019 Sep; 294(37):13681-13696. PubMed ID: 31341019
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
[TBL] [Abstract][Full Text] [Related]
15. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer.
Ji H; Sang M; Liu F; Ai N; Geng C
Pathol Res Pract; 2019 Apr; 215(4):697-704. PubMed ID: 30611621
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
17. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
18. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
[TBL] [Abstract][Full Text] [Related]
19. MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.
Lv ZD; Yang DX; Liu XP; Jin LY; Wang XG; Yang ZC; Liu D; Zhao JJ; Kong B; Li FN; Wang HB
Cell Physiol Biochem; 2017; 44(5):1785-1795. PubMed ID: 29216628
[TBL] [Abstract][Full Text] [Related]
20. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
